PDCD1 and melanoma: In a clinical trial in patients with previously untreated metastatic or unresectable melanoma (RELATIVITY‐047), inhibition of two immune checkpoints, LAG‐3 and PD‐1, provided a greater benefit with regard to progression‐free survival than inhibition of PD‐1 alone.39